Review ArticleClinical Review

Human Papillomavirus-Associated Head and Neck Cancer

Juan C. Nogues, Scott Fassas, Collin Mulcahy and Philip E. Zapanta
The Journal of the American Board of Family Medicine July 2021, 34 (4) 832-837; DOI: https://doi.org/10.3122/jabfm.2021.04.200588

References

  1. 1.↵
    National Cancer Institute Surveillance, Epidemiology, and End Results Program [Internet]. Oral cavity and pharynx cancer long-term trends in SEER age-adjusted incidence rates, 1975–2017 [cited 2020 Oct 13]. Available from: https://seer.cancer.gov/explorer/application.html?site=3&data_type=1&graph_type=1&compareBy=sex&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&hdn_stage=101&rate_type=1&advopt_precision=1&advopt_display=2.
  2. 2.↵
    1. Van Dyne EA,
    2. Henley SJ,
    3. Saraiya M,
    4. Thomas CC,
    5. Markowitz LE,
    6. Benard VB
    . Trends in human papillomavirus–associated cancers—United States, 1999–2015. MMWR 2018;67:918–24.
    OpenUrlCrossRef
  3. 3.↵
    1. Lassen P,
    2. Lacas B,
    3. Pignon J-P,
    4. et al
    . Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiother Oncol J Eur Soc Ther Radiol Oncol 2018;126:107–15.
    OpenUrl
  4. 4.↵
    1. Marur S,
    2. Forastiere AA
    . Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 2016;91:386–96.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Gillison ML,
    2. Chaturvedi AK,
    3. Anderson WF,
    4. Fakhry C
    . Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. JCO 2015;33:3235–42.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Mourad M,
    2. Jetmore T,
    3. Jategaonkar AA,
    4. Moubayed S,
    5. Moshier E,
    6. Urken ML
    . Epidemiological trends of head and neck cancer in the United States: a SEER population study. J Oral Maxillofac Surg 2017;75:2562–72.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mehanna H,
    2. Beech T,
    3. Nicholson T,
    4. et al
    . Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747–55.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Moore KA,
    2. Mehta V
    . The growing epidemic of HPV-positive oropharyngeal carcinoma: a clinical review for primary care providers. J Am Board Fam Med 2015;28:498–503.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Chaturvedi AK,
    2. Engels EA,
    3. Pfeiffer RM,
    4. et al
    . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. JCO 2011;29:4294–301.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Gillison ML,
    2. D'Souza G,
    3. Westra W,
    4. et al
    . Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407–20.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Gillison ML,
    2. Alemany L,
    3. Snijders PJF,
    4. et al
    . Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012;30:F34–54.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Timbang MR,
    2. Sim MW,
    3. Bewley AF,
    4. Farwell DG,
    5. Mantravadi A,
    6. Moore MG
    . HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccines Immunother 2019;15:1920–8.
    OpenUrl
  13. 13.↵
    1. Budu VA,
    2. Decuseară T,
    3. Balica NC,
    4. et al
    . The role of HPV infection in oropharyngeal cancer. Romanian J Morphol Embryol Rev Roum Morphol Embryol 2019;60:769–73.
    OpenUrl
  14. 14.↵
    1. Khalid MB,
    2. Ting P,
    3. Pai A,
    4. et al
    . Initial presentation of human papillomavirus-related head and neck cancer: a retrospective review. Laryngoscope 2019;129:877–82.
    OpenUrl
  15. 15.↵
    1. Georgopoulos R,
    2. Liu JC
    . Examination of the patient with head and neck cancer. Surg Oncol Clin N Am 2015;24:409–21.
    OpenUrl
  16. 16.↵
    GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) [package insert]. Whitehouse Station, NJ; Merck & Co., Inc; revised August 2020.
  17. 17.↵
    Centers for Disease Control and Prevention [Internet]. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2020 [cited 2020 Oct 13]. Available from: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#note-hpv.
  18. 18.↵
    Centers for Disease Control and Prevention [Internet]. HPV vaccine recommendations. 2020 [cited 2020 Oct 14]. Available from: https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html.
  19. 19.↵
    Centers for Disease Control and Prevention [Internet]. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. 2019 [cited 2020 Oct 14]. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm.
  20. 20.↵
    1. Mehta V,
    2. Holmes S,
    3. Master A,
    4. Leblanc B,
    5. Caldito LG,
    6. Bocchini J
    . Knowledge of HPV-related oropharyngeal cancer and use of human papillomavirus vaccines by pediatricians in Louisiana. J La State Med Soc 2017;169:37–42.
    OpenUrl
  21. 21.↵
    1. Elam-Evans LD,
    2. Yankey D,
    3. Singleton JA,
    4. et al
    . National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2019. MMWR 2020;69:1109–16.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Giuliano AR,
    2. Isaacs-Soriano K,
    3. Torres BN,
    4. et al
    . Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—the MAM Study. Vaccine 2015;33:5640–6.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Gupta A,
    2. Perkins RB,
    3. Ortega G,
    4. Feldman S,
    5. Villa A
    . Barrier use during oro-genital sex and oral human papillomavirus prevalence: analysis of NHANES 2009–2014. Oral Dis 2019;25:609–16.
    OpenUrl
  24. 24.↵
    1. Holway GV,
    2. Hernandez SM
    . Oral sex and condom use in a U.S. national sample of adolescents and young adults. J Adolesc Health 2018;62:402–10.
    OpenUrl
  25. 25.↵
    1. D'Souza G,
    2. Fakhry C,
    3. Sugar EA,
    4. et al
    . Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007;121:143–50. =.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Golusiński W,
    2. Golusińska-Kardach E
    . Current role of surgery in the management of. oropharyngeal cancer. Front Oncol 2019;9:388.
    OpenUrlPubMed
  27. 27.↵
    1. Lim GC,
    2. Holsinger FC,
    3. Li RJ
    . Transoral endoscopic head and neck surgery: the contemporary treatment of head and neck cancer. Hematol Oncol Clin North Am 2015;29:1075–92.
    OpenUrl
  28. 28.↵
    1. Achim V,
    2. Bolognone RK,
    3. Palmer AD,
    4. et al
    . Long-term functional and quality-of-life outcomes after transoral robotic surgery in patients with oropharyngeal cancer. JAMA Otolaryngol– Head Neck Surg 2018;144:18–27.
    OpenUrl
  29. 29.↵
    1. Sethia R,
    2. Yumusakhuylu AC,
    3. Ozbay I,
    4. et al
    . Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer: QOL outcomes of TORS for oropharyngeal cancer. Laryngoscope 2018;128:403–11.
    OpenUrl
  30. 30.↵
    1. Castellano A,
    2. Sharma A
    . Systematic review of validated quality of life and swallow outcomes after transoral robotic surgery. Otolaryngol Head Neck Surg 2019;161:561–7.
    OpenUrl
  31. 31.↵
    1. Nichols AC,
    2. Theurer J,
    3. Prisman E,
    4. et al
    . Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 2019;20:1349–59.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords